Zydus Lifesciences Limited and Sun Pharmaceutical Industries Limited (Sun Pharma) have entered into a licensing agreement to co-market an innovative drug for anaemia linked to kidney ailments.
Desidustat is the first-of-its-kind oral treatment for anemia associated with chronic kidney diseases (CKD) in India, the drug makers said.
Under the terms of the agreement, Zydus has granted Sun Pharma semi-exclusive rights to comarket the product in India under the brand name RYTSTAT. Zydus had launched the drug under the brand name Oxemia in 2022 and will continue to market it.
Zydus will receive an upfront licensing income and receive incomes based on achievement of pre-defined milestones. “Desidustat, which is one of the critical treatment options for CKD patients, has substantially improved the patients’ quality of life since it is more convenient to take an oral pill, instead of an injection that needs to be administered. We are pleased to join hands with Sun Pharma to expand the reach of this novel medicine by enabling access to more patients,” said a spokesperson for Zydus Lifesciences Ltd.
Kirti Ganorkar, CEO – India Business, Sun Pharma said: “This partnership will allow greater access to a critical therapy, helping millions of patients suffering from chronic kidney diseases.”
